Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Moodys
Dow
Boehringer Ingelheim
Mallinckrodt

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021842

See Plans and Pricing

« Back to Dashboard

NDA 021842 describes ACTOPLUS MET, which is a drug marketed by Takeda Pharms Usa and is included in two NDAs. It is available from one supplier. There are nine patents protecting this drug and two Paragraph IV challenges. Additional details are available on the ACTOPLUS MET profile page.

The generic ingredient in ACTOPLUS MET is metformin hydrochloride; pioglitazone hydrochloride. There are forty-nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the metformin hydrochloride; pioglitazone hydrochloride profile page.
Summary for 021842
Pharmacology for NDA: 021842
Suppliers and Packaging for NDA: 021842
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842 NDA Takeda Pharmaceuticals America, Inc. 64764-155 64764-155-18 180 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (64764-155-18)
ACTOPLUS MET metformin hydrochloride; pioglitazone hydrochloride TABLET;ORAL 021842 NDA Takeda Pharmaceuticals America, Inc. 64764-155 64764-155-41 4 CARTON in 1 TRAY (64764-155-41) > 1 BLISTER PACK in 1 CARTON > 7 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength500MG;EQ 15MG BASE
Approval Date:Aug 29, 2005TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Jan 22, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Feb 3, 2029Product Flag?YSubstance Flag?Delist Request?

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength850MG;EQ 15MG BASE
Approval Date:Aug 29, 2005TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Jan 22, 2027Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 021842

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Harvard Business School
Johnson and Johnson
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.